CEO wants to make Bavarian Nordic one of the world's largest vaccine companies

Paul Chaplin wants to achieve the goal, which will require annual sales of over USD 1bn, in 2025 at the latest.

CEO Paul Chaplin, Bavarian Nordic | Photo: PR/Bavarian Nordic

Becoming one of the world's largest companies that focuses exclusively on vaccines in 2025 at the latest will require the current yearly revenue to triple, says Paul Chaplin, CEO of Bavarian Nordic, to Danish financial daily Børsen.

"In my view, that goal equates to at least USD 1bn in sales. We are far from fulfilling that ambition right now," he says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs